---
title: "Chondromix"
canonical_url: https://peptidelibrary.app/library/chondromix
description: "Marketed cartilage-support peptide blend rather than a single characterised active ingredient, with composition varying between suppliers. Because it is a mixture, no single mechanism, sequence or pharmacokinetic profile applies to it, and no pivotal trial has evaluated any branded product under this name. Not FDA-approved and not a treatment for arthritis or joint disease."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Chondromix

Chondromix (also called Cartilage peptide complex) is a bioregulator. Chondromix is a marketed blend rather than a defined single compound, sold for cartilage and joint support. It has no single molecular mechanism because its composition is a mixture, and formulations differ between suppliers.

Marketed cartilage-support peptide blend rather than a single characterised active ingredient, with composition varying between suppliers. Because it is a mixture, no single mechanism, sequence or pharmacokinetic profile applies to it, and no pivotal trial has evaluated any branded product under this name. Not FDA-approved and not a treatment for arthritis or joint disease.

Also known as: Cartilage peptide complex.

Categories: Muscle/Recovery, Experimental.

## Classification

- Type: Bioregulator / research mixture
- Mechanism class: Short Peptide Bioregulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Chondromix is a marketed blend rather than a defined single compound, sold for cartilage and joint support. It has no single molecular mechanism because its composition is a mixture, and formulations differ between suppliers. Where it contains Khavinson-series peptides such as Cartalax, the proposed mechanism is that series' hypothesis of short peptides interacting with DNA promoter regions to influence chondrocyte gene expression — a claim resting on cell-culture and cytogenetic work from one research group. No pivotal trial has evaluated any branded Chondromix product, and the pharmacokinetics of the combination are uncharacterised.

Targets: Cartilage matrix (claimed).

Origin: Commercial peptide mixture; not a monographed drug.

## Properties

- Molecular formula: C15H28N4O7S
- Molecular weight: 408.47 g/mol
- CAS number: 168608-25-7
- Half-life: Not established

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019. 2019. Preclinical: in vitro (cells or tissue). Population: Human periodontal ligament stem cells in culture. GAP43 and nestin expression increased with the four-peptide combination and with KED alone. An independent effect of AED on those markers was not reported. Research on a related compound, not this one. Limitations: Studied an analog, not Chondromix itself; Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/30791821/)

## Safety

Side effects: Unknown; product-dependent.

Risks: Uncharacterized mixture; Research-only.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Chondromix is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Chondromix?

Marketed cartilage-support peptide blend rather than a single characterised active ingredient, with composition varying between suppliers. Because it is a mixture, no single mechanism, sequence or pharmacokinetic profile applies to it, and no pivotal trial has evaluated any branded product under this name. Not FDA-approved and not a treatment for arthritis or joint disease.

### How does Chondromix work?

Chondromix is a marketed blend rather than a defined single compound, sold for cartilage and joint support. It has no single molecular mechanism because its composition is a mixture, and formulations differ between suppliers.

### Is Chondromix FDA approved?

No. Chondromix is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What peptides are similar to Chondromix?

Compounds most often compared with Chondromix include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Class-level evidence — Peptides and Ageing](https://pubmed.ncbi.nlm.nih.gov/12374906/)
- [Class-level evidence — Tissue-specific effects of peptides](https://pubmed.ncbi.nlm.nih.gov/11713572/)
